Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI solutions for back and neck pain treatment, has announced the adjournment of its Annual Meeting of Stockholders. The meeting, originally scheduled for July 7, 2025, will be reconvened on July 21, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office.
The adjournment aims to solicit additional votes for proposals outlined in the company's May 13, 2025 proxy statement. The record date remains May 9, 2025, and previously submitted proxies will remain valid unless properly revoked. Stockholders can modify their votes until 11:59 p.m. Mountain Time on July 20, 2025.
Aclarion (NASDAQ: ACON), un'azienda tecnologica nel settore sanitario specializzata in soluzioni MRS e AI per il trattamento del dolore alla schiena e al collo, ha annunciato la sospensione della sua Assemblea Annuale degli Azionisti. L'incontro, originariamente previsto per il 7 luglio 2025, si terrà invece il 21 luglio 2025 alle 9:30 ora della Montagna presso la sede dell'azienda a Broomfield, Colorado.
La sospensione ha lo scopo di raccogliere ulteriori voti per le proposte indicate nel documento proxy dell'azienda del 13 maggio 2025. La data di riferimento rimane il 9 maggio 2025, e le deleghe già inviate resteranno valide a meno che non vengano revocate correttamente. Gli azionisti possono modificare il proprio voto fino alle 23:59 ora della Montagna del 20 luglio 2025.
Aclarion (NASDAQ: ACON), una empresa de tecnología sanitaria especializada en soluciones MRS e IA para el tratamiento del dolor de espalda y cuello, ha anunciado la suspensión de su Junta Anual de Accionistas. La reunión, originalmente programada para el 7 de julio de 2025, se reanudará el 21 de julio de 2025 a las 9:30 a.m. hora de la montaña en la oficina de la empresa en Broomfield, Colorado.
La suspensión tiene como objetivo solicitar votos adicionales para las propuestas detalladas en la declaración proxy de la empresa del 13 de mayo de 2025. La fecha de registro sigue siendo el 9 de mayo de 2025, y los poderes previamente enviados seguirán siendo válidos a menos que se revoquen correctamente. Los accionistas pueden modificar sus votos hasta las 11:59 p.m. hora de la montaña del 20 de julio de 2025.
Aclarion (NASDAQ: ACON)은 척추 및 목 통증 치료를 위한 MRS 및 AI 솔루션에 특화된 헬스케어 기술 회사로서, 연례 주주총회 연기를 발표했습니다. 원래 2025년 7월 7일로 예정되었던 회의는 2025년 7월 21일 오전 9시 30분(산악 표준시)에 콜로라도 브룸필드에 위치한 회사 사무실에서 재개됩니다.
이번 연기는 2025년 5월 13일 회사 위임장 설명서에 명시된 제안에 대한 추가 투표를 요청하기 위한 것입니다. 기준일은 2025년 5월 9일로 유지되며, 이미 제출된 위임장은 적절히 철회되지 않는 한 유효합니다. 주주들은 2025년 7월 20일 산악 표준시 기준 오후 11시 59분까지 투표를 변경할 수 있습니다.
Aclarion (NASDAQ : ACON), une entreprise technologique dans le domaine de la santé spécialisée dans les solutions MRS et IA pour le traitement des douleurs au dos et au cou, a annoncé le report de son Assemblée Générale Annuelle des Actionnaires. La réunion, initialement prévue le 7 juillet 2025, sera reprise le 21 juillet 2025 à 9h30, heure des Rocheuses dans les bureaux de l'entreprise à Broomfield, Colorado.
Ce report vise à recueillir des votes supplémentaires pour les propositions présentées dans la déclaration de procuration de l'entreprise du 13 mai 2025. La date d'enregistrement reste le 9 mai 2025, et les procurations déjà soumises resteront valides sauf révocation appropriée. Les actionnaires peuvent modifier leur vote jusqu'à 23h59, heure des Rocheuses, le 20 juillet 2025.
Aclarion (NASDAQ: ACON), ein Unternehmen für Gesundheitstechnologie, das sich auf MRS- und KI-Lösungen zur Behandlung von Rücken- und Nackenschmerzen spezialisiert hat, hat die Vertagung seiner Jahreshauptversammlung der Aktionäre bekannt gegeben. Die ursprünglich für den 7. Juli 2025 geplante Versammlung wird am 21. Juli 2025 um 9:30 Uhr Mountain Time in der Firmenzentrale in Broomfield, Colorado, fortgesetzt.
Die Vertagung dient dazu, weitere Stimmen für die in der Proxy-Erklärung des Unternehmens vom 13. Mai 2025 aufgeführten Vorschläge einzuholen. Das Stichtdatum bleibt der 9. Mai 2025, und zuvor eingereichte Vollmachten bleiben gültig, sofern sie nicht ordnungsgemäß widerrufen werden. Aktionäre können ihre Stimmen bis zum 20. Juli 2025 um 23:59 Uhr Mountain Time ändern.
- None.
- None.
- Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time
BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the “SEC”) on May 13, 2025.
The Annual Meeting will be reconvened on Monday, July 21, 2025, at 9:30 a.m. Mountain Time, and will continue to be held at the Company’s corporate office at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
The record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains May 9, 2025. Stockholders as of May 9, 2025, the record date for the Annual Meeting, are encouraged to vote as soon as possible.
Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders can change their vote at any time before the Annual Meeting by returning a signed proxy with a later date or transmitting a subsequent vote over the Internet by 11:59 p.m. Mountain Time on July 20, 2025.
Important Information
This material may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on July 21, 2025. In connection with the Annual Meeting, the Company filed a definitive proxy statement with the SEC on May 13, 2025. BEFORE MAKING ANY VOTING DECISIONS, STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The proxy materials have been made available to shareholders who are entitled to vote at the Annual Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at sec.gov or the Company’s website https://investors.aclarion.com/sec-filings.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), and a proprietary biomarker to optimize clinical treatments. Aclarion's technology addresses the
Forward Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" including statements about the Annual Meeting. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. We have based these forward-looking statements on our current assumptions, expectations, and projections about future events. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “will,” "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. No information in this press release should be construed as any indication whatsoever of our future revenues, stock price, or results of operations. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's filings with the Securities and Exchange Commission including those discussed under the heading “Risk Factors” in our most recently filed reports on Forms 10-K and 10-Q.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
FAQ
When is Aclarion's (ACON) rescheduled Annual Meeting of Stockholders?
What is the record date for Aclarion's (ACON) 2025 Annual Meeting?
How can ACON stockholders change their vote for the Annual Meeting?
What does Aclarion (ACON) specialize in?
Where can investors find Aclarion's proxy materials?
